Drug Therapy

1. Is lenalidomide a new standard treatment for myelodysplastic syndrome?

Author
Kuendgen A;
Institution
A Kuendgen is a Clinician and Researcher in the Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University, Dusseldorf, Germany.
Journal
Nat Clin Pract Oncol. 2007 May 15;.

2. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.

Author
Knipp S; Hildebrand B; Kundgen A; Giagounidis A; Kobbe G; Haas R; Aul C; Gattermann N; Germing U;
Institution
Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine University, Dusseldorf, Germany. sabineknipp@hotmail.com
Journal
Cancer. 2007 Jul 15;110(2):345-52.
Abstract URL
Click here to view abstract

3. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.

Author
Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E; Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E;
Institution
Journal
Br J Haematol. 2007 Aug;138(4):555-7. Epub 2007 Jun 25.

4. The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.

Author
Armand JP; Burnett AK; Drach J; Harousseau JL; Lowenberg B; San Miguel J; Armand JP; Burnett AK; Drach J; Harousseau JL; Lowenberg B; San Miguel J;
Institution
Institut Gustave-Roussy, Dept. of Medicine, 39 Rue Camille-Desmoulins, Villejuif Cedex 94805, France. armand.jean-pierre@claudiusregaud.fr
Journal
Oncologist. 2007 Mar;12(3):281-90.
Abstract URL
Click here to view abstract

5. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.

Author
Kantarjian HM; O'Brien S; Huang X; Garcia-Manero G; Ravandi F; Cortes J; Shan J; Davisson J; Bueso-Ramos CE; Issa JP;
Institution
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org
Journal
Cancer. 2007 Mar 15;109(6):1133-7.
Abstract URL
Click here to view abstract

6. Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000-4000 IU vitamin D(3)).

Author
Molnar I; Stark N; Lovato J; Powell BL; Cruz J; Hurd DD; Mathieu JS; Chen TC; Holick MF; Cambra S; McQuellon RP; Schwartz GG;
Institution
Journal
Leukemia. 2007 May;21(5):1089-92. Epub 2007 Mar 8.

7. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.

Author
Porter J; Galanello R; Saglio G; Neufeld EJ; Vichinsky E; Cappellini MD; Olivieri N; Piga A; Cunningham MJ; Soulieres D; Gattermann N; Tchernia G; Maertens J; Giardina P; Kwiatkowski J; Quarta G; Jeng M; Forni GL; Stadler M; Cario H; Debusscher L; Della Porta M; Cazzola M; Greenberg P; Alimena G; Rabault B; Gathmann I; Ford JM; Alberti D; Rose C;
Institution
University College London, London, UK. j.porter@ucl.ac.uk
Journal
Eur J Haematol. 2008 Feb;80(2):168-76. Epub 2007 Nov 17.
Abstract URL
Click here to view abstract

8. Decitabine: in myelodysplastic syndromes.

Author
McKeage K; Croom KF;
Institution
Adis International Limited, 51 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand. demail@adis.co.nz
Journal
Drugs. 2006;66(7):951-8.
Abstract URL
Click here to view abstract

9. Treatment of myelodysplastic syndromes with exogenous erythropoietin: a new therapeutic paradigm.

Author
Mundle SD; Raza A;
Institution
Journal
Leukemia. 2006 Sep;20(9):1481-3.

10. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.

Author
Rzepecki P; Sarosiek T; Szczylik C; Rzepecki P; Sarosiek T; Szczylik C;
Institution
Department of Clinical Oncology, BMT Unit, Central Clinical Hospital Ministry of National Defence, 128 Szaserow Street, 00-909 Warsaw, Poland. piotr_rzepecki1@poczta.onet.pl
Journal
Jpn J Clin Oncol. 2006 Jan;36(1):46-9. Epub 2006 Jan 19.
Abstract URL
Click here to view abstract

11. Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes.

Author
Kurtin S; Sokol L;
Institution
University of Arizona, Arizona Cancer Center, Tucson, 85724, USA. skurtin@umcaz.edu
Journal
Cancer Control. 2006 Dec;13 Suppl:26-31.
Abstract URL
Click here to view abstract

12. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.

Author
Fenaux P; Raza A; Mufti GJ; Aul C; Germing U; Kantarjian H; Cripe L; Kerstens R; De Porre P; Kurzrock R;
Institution
Journal
Blood. 2007 May 15;109(10):4158-63. Epub 2007 Jan 30.
Abstract URL
Click here to view abstract

13. Thalidomide therapy in adult patients with myelodysplastic syndrome: a north central cancer treatment group phase II trial.

Author
Musto P;
Institution
Journal
Cancer. 2007 Mar 15;109(6):1211-2; author reply 1212.

14. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Author
Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA; Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
Institution
Division of Hematology/Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA. lewis.silverman@mssm.edu
Journal
J Clin Oncol. 2006 Aug 20;24(24):3895-903.
Abstract URL
Click here to view abstract